Dashboard: Filter Bricks
Main page content
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
The National report presents indicators as measured through the 2019 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.
This wallet card is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging parents to talk with their kids about opioids.
This flyer is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging parents to talk with their kids about opioids.
This wallet card is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging military parents to talk with their kids about opioids.
Displaying 1 - 10 out of 31